Elevated levels of fibroblast growth factor 23 may be linked with heart failure risk
Click Here to Manage Email Alerts
Key takeaways:
- During a median 10.8 years follow-up, researchers observed 295 hospitalizations for heart failure with preserved ejection fraction.
- Rate of total heart failure events increased with higher fibroblast growth factor 23 quartiles.
Elevated levels of fibroblast growth factor 23 may be associated with an increased risk for heart failure in adults with chronic kidney disease, according to a recently published study.
“Heart failure is a prominent comorbidity among patients with chronic kidney disease,” Alexander S. Leidner, MD, of the Northwestern University Feinberg School of Medicine in Chicago, Illinois, and colleagues, wrote in the study. “We examined the associations between baseline [fibroblast growth factor 23 (FGF23)] and first [heart failure (HF)] hospitalization across HF subtypes among participants with no prior history of HF.”
The Chronic Renal Insufficiency Cohort prospective study, which included 3,502 patients, aimed to investigate the relationship between FGF23 and HF risk among individuals with CKD. Researchers investigated potential links between FGF23 and incident hospitalization for HF by subtype.
Outcomes included incident HF by subtype and total HF hospitalization.
HF categorized as HF with preserved ejection fraction, HF with reduced ejection fraction and HF with unknown ejection fraction.
At a median follow-up time of 10.8 years, researchers observed 295 hospitalizations for HF with preserved ejection fraction, 242 hospitalizations for HF with reduced ejection fraction and 156 hospitalizations for HF with unknown ejection fraction. The rate of total HF events increased with higher FGF23 quartiles. Compared with patients in the first quartile, patients in the fourth quartile had a rate ratio of 1.81 for total HF events.
“Our finding that elevated FGF23 is associated with increased risks of all HF subtypes provides further support for continued research aimed at testing elevated FGF23 as a potential therapeutic target for prevention and treatment of HF among individuals with CKD,” the authors wrote.
Collapse
Read more about
Click Here to Manage Email Alerts